-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ICP-189 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ICP-189 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ICP-189 in Solid Tumor Drug Details: ICP-189 is under development for the...
-
Sector Analysis
ICP Monitoring Devices Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
ICP Monitoring Devices Market Report Overview The ICP monitoring devices market was valued at $163.7 million in 2023. The market will grow at a CAGR of more than 2% from 2023 to 2033. In most countries, traumatic brain injury (TBI) is the primary cause of ICP monitoring device usage. Measurement of ICP helps in the detection of brain damage and initiation of therapeutic intervention. ICP monitoring using External Ventricular Drainage (EVD) is considered the gold standard as the technique allows...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zurletrectinib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zurletrectinib in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zurletrectinib in Solid Tumor Drug Details: Zurletrectinib (ICP-723) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orelabrutinib in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orelabrutinib in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orelabrutinib in Follicular Lymphoma Drug Details: Orelabrutinib (Inokai) acts as an anti-cancer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orelabrutinib in Nodal Marginal Zone B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orelabrutinib in Nodal Marginal Zone B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orelabrutinib in Nodal Marginal Zone B-Cell Lymphoma Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orelabrutinib in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orelabrutinib in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orelabrutinib in Extranodal Marginal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orelabrutinib in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orelabrutinib in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orelabrutinib in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orelabrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orelabrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orelabrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orelabrutinib in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orelabrutinib in Marginal Zone B-cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orelabrutinib in Marginal Zone B-cell Lymphoma Drug Details: Orelabrutinib (Inokai)...
-
Sector Analysis
BRIC ICP Procedures Count and Forecast to 2030
BRIC ICP Procedures Market Report Overview The total number of ICP Procedures performed in BRIC was 134,298 in 2022. This procedure includes the insertion of a pressure monitor through the skull to measure the pressure inside the patient’s head. BRIC ICP Procedures Market Outlook, 2022-2030 (Number of Procedures) Buy the Full Report and Download a Free Sample Report for More Insights on the BRIC ICP Procedures Market Forecast The BRIC ICP Procedures market research report is a comprehensive databook report...